What's hot!

View all perspectives
What's Hot

Dietary Interventions in PsA

Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.

Watch video →

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise

Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London. 

Watch video →

Renal Biopsies in SLE

Dr. Andrea Fava reporting from EULAR 2026 in London.

Watch video →

RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk

Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London 

Watch video →

Combination Biologics in PsA: MRI Findings from AFFINITY

Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.  

Watch video →

Day 4 Recap: EULAR 2026

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.

Watch video →

EULAR 2026 Recommendations: Immunization

Dr. Jiha Lee reporting from EULAR 2026 in London.

Watch video →

Making Methotrexate More Effective

Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London

Watch video →

Are we failing in the treatment of RA-ILD?

Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.

Watch video →

How Many CAR-Ts Do We Need to Test Drive?

Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.

Watch video →

Day 3 Recap: EULAR 2026

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288

Watch video →

New axSpA Criteria: Who gets left out?

Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.  

Watch video →

PsA Potpourri: Probiotics & Head-to-Head Data

Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.

Watch video →
CAR T on purple background

5 years since Patient ID001: Progress on CAR-T Therapy in RMD

Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?

Read more →

BMI Outranks Treatment in PsA Outcomes?

Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.

Watch video →

BE BOLD: Going Where No PsA Trial Has Gone Before

Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London  

Watch video →
holding hands together support frail

New biomarkers in RA: Who to treat, Who to watch, Who to taper?

Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.

Read more →

Debate: Combination Therapies for Inflammatory Arthritis?

Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.

Watch video →
      Effect of IL-17i on metabolic profile and CV safety in PsA/axSpA

      169 pts 12mo

      -IL-17i no MACE reported
      -CRP reduced 4.

      Aurelie Najm AurelieRheumo

      6 days 15 hours ago
      Effect of IL-17i on metabolic profile and CV safety in PsA/axSpA 169 pts 12mo -IL-17i no MACE reported -CRP reduced 4.8 → 2.9 mg/L, p<0.001 -79% systemic inflammatory response -Lipids stable (LDL, TG, TC) 12mo follow up is probably too short though #POS0375 #EULAR2026 https://t.co/u6cvB5YYGq
      #OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred

      Mrinalini Dey DrMiniDey

      6 days 15 hours ago
      #OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred oral JAKi over SC TNFi (55% vs 45%) Importantly, own choice led to higher treatment satisfaction, better drug survival & fewer adverse events. @RheumNow #EULARBest https://t.co/iI1n2OGzqY
      Prospective study of RVZ immunogenicity = heterogeneous cellular immunity across RMDs

      12mo 150 pts
      -CD4+ gE-T-cell res

      Aurelie Najm AurelieRheumo

      6 days 15 hours ago
      Prospective study of RVZ immunogenicity = heterogeneous cellular immunity across RMDs 12mo 150 pts -CD4+ gE-T-cell response peaks mo 3 -Response seen in axSpA + GCA, but not RA -25% of patients no CMI increase after vaccination Consistent w/other vaccine cellular imm profiles https://t.co/yvDLSHh4Bj
      #OP0203 #EULAR2026: low-dose blinatumomab in multidrug-resistant RA introduced the intriguing concept of “immune dimmi

      Mrinalini Dey DrMiniDey

      6 days 15 hours ago
      #OP0203 #EULAR2026: low-dose blinatumomab in multidrug-resistant RA introduced the intriguing concept of “immune dimming”, transient B-cell depletion that appeared to restore responsiveness to previously failed DMARDs, JAK inhibitors and TNFi in several patients. @RheumNow
      Frailty as a long term outcome in RA

      Higher frailty in RA vs ctrls HR 1.76 in 910 matched pairs.

      -10y: 30.6% vs 19.1%

      Aurelie Najm AurelieRheumo

      6 days 15 hours ago
      Frailty as a long term outcome in RA Higher frailty in RA vs ctrls HR 1.76 in 910 matched pairs. -10y: 30.6% vs 19.1% -20y: 53.8% vs 35.3% -Stronger in recent RA (HR 2.38) Driven by age, smoking, comorbidity, steroids/biologics not RF/CCP. Preventive interventions needed https://t.co/pcJrE73G5O
      TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials
      8 domains: mucocutaneous, arthritis, hemolytic anem

      sheila RHEUMarampa

      6 days 15 hours ago
      TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials 8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis Developed via multistage consensus process Higher pt enrollment potential? POS1068 @RheumNow #EULAR2026 https://t.co/W614xZV7TX
      Catching up on #EULAR2026 “Advanced management in RA” session: #OP0202 reported positive phase 2b RENOIR data for ro

      Mrinalini Dey DrMiniDey

      6 days 15 hours ago
      Catching up on #EULAR2026 “Advanced management in RA” session: #OP0202 reported positive phase 2b RENOIR data for rosnilimab, a selective pathogenic T-cell depleter, with significant improvements in DAS28-CRP, ACR responses and CDAI LDA vs placebo in RA. @RheumNow https://t.co/IKKtakxpya
      Machine learning identifies a “vulnerable” phenotype in older RA patients n=275

      -51% “vulnerable”
      -Worse grip s

      Aurelie Najm AurelieRheumo

      6 days 15 hours ago
      Machine learning identifies a “vulnerable” phenotype in older RA patients n=275 -51% “vulnerable” -Worse grip strength, gait speed & SARC-F -Higher disability (HAQ 1.56 vs 0.64) -More fatigue, poorer QoL -Higher DAS28 despite greater biologic exposure Suggests we should assess https://t.co/bv1FbTxGKR
      #EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the pr

      Md Yuzaiful Md Yusof Yuz6Yusof

      6 days 15 hours ago
      #EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi
      Depression at RA diagnosis did not predict short-term CV events in a nationwide early RA cohort

      -17,669 early RA pts
      -7

      Aurelie Najm AurelieRheumo

      6 days 15 hours ago
      Depression at RA diagnosis did not predict short-term CV events in a nationwide early RA cohort -17,669 early RA pts -7.3% BL depression -Median follow-up 1.2 years -No association w/ CV hospitalisation after adjustment (sHR 1.05) Reassuring short-term data, longer follow-up https://t.co/XmMVGY1VlI
      How many ‘cars’ are there?
      crowded #CAR-T ‘driving’ innovation at
      #EULAR2026

      >90 abstracts w CAR-T in title

      Janet Pope Janetbirdope

      6 days 15 hours ago
      How many ‘cars’ are there? crowded #CAR-T ‘driving’ innovation at #EULAR2026 >90 abstracts w CAR-T in title Lessons learned Maybe #immune #reset is not always the goal ➡️vs ’#immune #dimming How long are effects? safety looks good PT selection is key Early, no damage @RheumNow https://t.co/6jii5MBJcJ
      One of the highlights of #EULAR2026 for me:

      ♀️The "This Is a Woman's World" session

      I recapped 8 must-know abstra

      Nelly ZIADE 🍀 Nellziade

      6 days 15 hours ago
      One of the highlights of #EULAR2026 for me: ♀️The "This Is a Woman's World" session I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬 https://t.co/3jwJIegGg4 via @YouTube @ArLARheumatolog https://t.co/Azvkl2sjdu
      Failure to achieve early remission RA asso w/ non-inflammatory pain

      NORD-STAR 526 early RA pts)
      no remission at 24 wks

      Aurelie Najm AurelieRheumo

      6 days 15 hours ago
      Failure to achieve early remission RA asso w/ non-inflammatory pain NORD-STAR 526 early RA pts) no remission at 24 wks increased risk of 48wk • unacceptable pain (OR ~6) • refractory pain (OR ~6) • fibromyalgic RA (OR ~16) Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw
      MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA
      6 days 15 hours ago
      Even with tight T2T, ARCTIC 10yr follow-up (n=170) show 9% had RA-ILD on HRCT, plus another 19% with non-specific inters

      Jiha Lee JihaRheum

      6 days 16 hours ago
      Even with tight T2T, ARCTIC 10yr follow-up (n=170) show 9% had RA-ILD on HRCT, plus another 19% with non-specific interstitial findings. Male sex and older age were risk factors. Seropositivity was not. Vigilance remains essential. @RheumNow #EULAR2026 POS1270

      Podcasts

      • RA Topic Podcast compilation
      • PsA Topic Podcast compilation
      • CAR T Topic compilation

      Catch up on Conference Podcasts

      ×